[ARS] VivoSim Labs, INC. SEC Filing

Filing Impact

(No impact)

Filing Sentiment

(Neutral)

Form Type

ARS

11/06/2025 - 04:52 PM

ARS - VivoSim Labs, INC.

ARS Filing - VivoSim Labs, INC.

This filing is available as a PDF document.

Filing Type: ARS

Company: VivoSim Labs, INC. (VIVS)

Acceptance Date: 2025-11-06T16:52:12.000Z

View PDF Document

Source: View Original Filing on SEC EDGAR

VivoSim Labs Inc

NASDAQ:VIVS

VIVS Rankings

#6523 Ranked by Market Cap

N/A Ranked by Dividends

VIVS Latest News

Aug 14, 2025

VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer

May 13, 2025

VivoSim’s NAMKind™ Intestine Wins Blue Ribbon Award at Digestive Disease Week Conference

May 7, 2025

VivoSim Presents Best-in-Class Liver Toxicology Prediction Results at Digestive Disease Week Conference

Apr 24, 2025

VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market

VIVS Latest SEC Filings

Nov 19, 2025

[Form 4] VivoSim Labs, INC. Insider Trading Activity

Nov 6, 2025

[10-Q] VivoSim Labs, INC. Quarterly Earnings Report

Nov 3, 2025

[DEF 14A] VivoSim Labs, INC. Definitive Proxy Statement

Sep 25, 2025

[RW] VivoSim Labs, INC. SEC Filing

Aug 28, 2025

[S-8] VivoSim Labs, Inc. Employee Benefit Plan Registration

VIVS Stock Data

Market Cap 5.66M

Float 2.58M

Insiders Ownership 1.13%

Institutions Ownership 9.02%

Short Percent 1.46%

Industry Biotechnology

Sector Biological Products, (no Disgnostic Substances)

Website Link

Country United States

City SAN DIEGO